O’Melveny advised Vivo Capital as the leader of an investment syndicate in the investment syndicate’s definitive agreement to acquire Canadian medical device maker Angiotech Pharmaceuticals. Vivo…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now